Table of Contents
PLAINSBORO, N.J. – Novo Nordisk has announced that the U.S. Food and Drug Administration has officially determined that the shortage of its prescription GLP-1 medications, Wegovy and Ozempic, has been resolved. According to the FDA, the U.S. supply of these FDA-approved semaglutide treatments now meets or exceeds both current and projected demand.
In response to increasing demand, Novo Nordisk has ramped up manufacturing efforts, operating production facilities around the clock to ensure continuous shipments of all doses to wholesalers. The company has invested $6.5 billion in expanding its U.S. manufacturing capacity this year alone.
"We are pleased the FDA has declared that the supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding nationwide demand," said Dave Moore, Executive Vice President of U.S. Operations and Global Business Development and President of Novo Nordisk Inc. "No one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients."
Following the FDA's determination, making or selling unauthorized compounded versions of semaglutide medicines—such as those replicating Ozempic or Wegovy—is illegal under compounding laws, with rare exceptions.
To further support patient access, Novo Nordisk has introduced the Find My Meds app, an AI-powered tool designed to help users locate available doses of Wegovy at retail pharmacies. This initiative aims to assist individuals in finding their prescriptions more efficiently, ensuring continuity of care and improved health outcomes.
For more information, visit Novo Nordisk’s website.
